Skip to main content
Medical information Clinical review pending

Genetic Testing

Beta Thalassemia-9 Common Mutations Screening (Single)

This genetic test screens for nine common mutations linked to Beta Thalassemia, a blood disorder affecting hemoglobin. Early detection aids in management and family planning.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Peripheral blood sample (EDTA tube). Confirm specific requirements with the laboratory before booking.
Results
Confirm turnaround time with the laboratory before booking.
Preparation
No special preparation is required for this test. However, confirm with the laboratory before booking.
Test priceKSh 10,500

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Beta Thalassemia-9 Common Mutations Screening (Single) test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Family history of Beta Thalassemia or related blood disorders.
  • ✓Symptoms suggestive of anemia, fatigue, or weakness.
  • ✓Individuals planning pregnancy or with a partner known to be a carrier.
  • ✓Pre-surgical assessment.
  • ✓Unexplained blood disorders.
  • ✓Genetic counseling.
02

In plain language

What this test helps you understand

This test helps identify individuals carrying common mutations for Beta Thalassemia, aiding in diagnosis, carrier screening, and genetic counseling. It informs management strategies and family planning decisions.
The Beta Thalassemia-9 Common Mutations Screening (Single) is a specialized genetic test designed to detect specific mutations in the HBB gene associated with Beta Thalassemia. This blood disorder impacts the body's ability to produce hemoglobin, which is essential for carrying oxygen in red blood cells. Early detection through this test is crucial for effective management and treatment, allowing individuals and their families to take proactive steps for their health. This screening identifies the presence of nine common mutations known to cause Beta Thalassemia. By analyzing a sample of peripheral blood using the End Point PCR method, the test provides insights into the genetic factors contributing to this condition. Understanding your genetic status can inform healthcare decisions and family planning.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is required for this test. However, confirm with the laboratory before booking.
SamplePeripheral blood sample (EDTA tube). Confirm specific requirements with the laboratory before booking.
MethodologyEnd Point PCR (Polymerase Chain Reaction) analysis of peripheral blood.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test screens for only nine common mutations associated with Beta Thalassemia. It may not detect rarer mutations. A negative result does not completely rule out the possibility of Beta Thalassemia. Results should be interpreted by a healthcare professional.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Beta Thalassemia is an inherited blood disorder where the body makes less hemoglobin than normal, leading to anemia.
Early detection helps in managing the condition, understanding risks, and making informed family planning decisions.
A positive result indicates the presence of one or more of the nine screened mutations. Discuss the implications with your doctor.
This test screens for nine common mutations. It may not detect rarer forms. Consult your doctor for comprehensive evaluation.
Generally, no special preparation is needed, but please confirm with the laboratory before your appointment.
You can book by calling or WhatsApping us at +254711564616. We offer services in Nairobi, Mombasa, Kisumu, and home sample collection.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp